Literature DB >> 24811494

Genentech to salvage anti-MET antibody with subgroup analysis.

Cormac Sheridan.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24811494     DOI： 10.1038/nbt0514-399

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  6 in total

1.  The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation.

Authors:  L Naldini; E Vigna; R Ferracini; P Longati; L Gandino; M Prat; P M Comoglio
Journal:  Mol Cell Biol       Date:  1991-04       Impact factor: 4.272

Review 2.  Targeting the HGF/Met signaling pathway in cancer therapy.

Authors:  Fabiola Cecchi; Danie C Rabe; Donald P Bottaro
Journal:  Expert Opin Ther Targets       Date:  2012-04-25       Impact factor: 6.902

3.  A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity.

Authors:  Shane A Olwill; Christian Joffroy; Hendrik Gille; Elisa Vigna; Gabriele Matschiner; Andrea Allersdorfer; Bradley M Lunde; Jakub Jaworski; James F Burrows; Cristina Chiriaco; Hans Jürgen Christian; Martin Hülsmeyer; Stefan Trentmann; Kristian Jensen; Andreas M Hohlbaum; Laurent Audoly
Journal:  Mol Cancer Ther       Date:  2013-09-03       Impact factor: 6.261

4.  Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.

Authors:  Mark Merchant; Xiaolei Ma; Henry R Maun; Zhong Zheng; Jing Peng; Mally Romero; Arthur Huang; Nai-ying Yang; Merry Nishimura; Joan Greve; Lydia Santell; Yu-Wen Zhang; Yanli Su; Dafna W Kaufman; Karen L Billeci; Elaine Mai; Barbara Moffat; Amy Lim; Eileen T Duenas; Heidi S Phillips; Hong Xiang; Judy C Young; George F Vande Woude; Mark S Dennis; Dorothea E Reilly; Ralph H Schwall; Melissa A Starovasnik; Robert A Lazarus; Daniel G Yansura
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-23       Impact factor: 11.205

5.  Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product.

Authors:  D P Bottaro; J S Rubin; D L Faletto; A M Chan; T E Kmiecik; G F Vande Woude; S A Aaronson
Journal:  Science       Date:  1991-02-15       Impact factor: 47.728

6.  MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Authors:  Jeffrey A Engelman; Kreshnik Zejnullahu; Tetsuya Mitsudomi; Youngchul Song; Courtney Hyland; Joon Oh Park; Neal Lindeman; Christopher-Michael Gale; Xiaojun Zhao; James Christensen; Takayuki Kosaka; Alison J Holmes; Andrew M Rogers; Federico Cappuzzo; Tony Mok; Charles Lee; Bruce E Johnson; Lewis C Cantley; Pasi A Jänne
Journal:  Science       Date:  2007-04-26       Impact factor: 47.728
  6 in total
  8 in total

1.  Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody.

Authors:  Simona Cignetto; Chiara Modica; Cristina Chiriaco; Lara Fontani; Paola Milla; Paolo Michieli; Paolo M Comoglio; Elisa Vigna
Journal:  Mol Oncol       Date:  2016-03-28       Impact factor: 6.603

2.  Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.

Authors:  Mansoureh Sameni; Elizabeth A Tovar; Curt J Essenburg; Anita Chalasani; Erik S Linklater; Andrew Borgman; David M Cherba; Arulselvi Anbalagan; Mary E Winn; Carrie R Graveel; Bonnie F Sloane
Journal:  Clin Cancer Res       Date:  2015-10-02       Impact factor: 12.531

Review 3.  Effective implementation of novel MET pharmacodynamic assays in translational studies.

Authors:  Apurva K Srivastava; Tony Navas; William G Herrick; Melinda G Hollingshead; Donald P Bottaro; James H Doroshow; Ralph E Parchment
Journal:  Ann Transl Med       Date:  2017-01

4.  SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models.

Authors:  Chang-Yong Yang; Lei Wang; Xing Sun; Mi Tang; Hai-Tian Quan; Lian-Shan Zhang; Li-Guang Lou; Shao-Hua Gou
Journal:  Acta Pharmacol Sin       Date:  2019-01-14       Impact factor: 6.150

5.  Prognostic impact and potential interaction of EGFR and c-Met in the progression of esophageal squamous cell carcinoma.

Authors:  Haixing Wang; Dongxian Jiang; Qi Song; Chen Xu; Yuan Shi; Xiaojing Li; Jie Huang; Yifan Xu; Akesu Sujie; Haiying Zeng; Yunshi Zhong; Lijie Tan; Yingyong Hou
Journal:  Tumour Biol       Date:  2016-01-25

Review 6.  Development of antibody-based c-Met inhibitors for targeted cancer therapy.

Authors:  Dongheon Lee; Eun-Sil Sung; Jin-Hyung Ahn; Sungwon An; Jiwon Huh; Weon-Kyoo You
Journal:  Immunotargets Ther       Date:  2015-02-09

7.  Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification.

Authors:  Jieyi Wang; Liliane Goetsch; Lora Tucker; Qian Zhang; Alexandra Gonzalez; Kedar S Vaidya; Anatol Oleksijew; Erwin Boghaert; Minghao Song; Irina Sokolova; Ekaterina Pestova; Mark Anderson; William N Pappano; Peter Ansell; Anahita Bhathena; Louie Naumovski; Nathalie Corvaia; Edward B Reilly
Journal:  BMC Cancer       Date:  2016-02-16       Impact factor: 4.430

8.  Tumor Inhibitory Effect of IRCR201, a Novel Cross-Reactive c-Met Antibody Targeting the PSI Domain.

Authors:  Hyunkyu Park; Donggeon Kim; Eunmi Kim; Jason K Sa; Hee Won Lee; Suji Yu; Jiwon Oh; Seok-Hyung Kim; Yeup Yoon; Do-Hyun Nam
Journal:  Int J Mol Sci       Date:  2017-09-13       Impact factor: 5.923
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.